Exome Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Exome Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-85,517	Closed	-$3.44M	–	53
2026 Q1	$3.44M	Sell	85,517 -50,332	-37%	-$1.08M	1.78%	21
2025 Q4	$3.41M	Buy	+135,849	New	+$3.19M	1.63%	23
2025 Q3	–	Sell	-98,600	Closed	-$1.71M	–	74
2025 Q2	$1.71M	Buy	+98,600	New	+$1.83M	1.27%	37
2025 Q1	–	Sell	-119,467	Closed	-$3.81M	–	63
2024 Q4	$3.81M	Buy	119,467 +19,100	+19%	+$574K	2.86%	12
2024 Q3	$2.89M	Buy	100,367 +53,467	+114%	+$1.98M	1.96%	22
2024 Q2	$1.8M	Buy	+46,900	New	+$2.12M	1.6%	30
2024 Q1	–	Sell	-7,249	Closed	-$434K	–	54
2023 Q4	$434K	Buy	+7,249	New	+$368K	0.43%	48

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Exome Asset Management's APLS Position: Q2 2026 in Review

Exome Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 85,517 shares — an estimated $3.44M sold.

Exome Asset Management first reported a position in APLS in Q4 2023 and held it in 7 quarters. The position peaked at $3.81M in Q4 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Exome Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Exome Asset Management sold 85,517 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.44M.
Exome Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Exome Asset Management's Apellis Pharmaceuticals position peaked at $3.81M in Q4 2024.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.